Leading the New Frontier of Inflammatory Care
Transforming the $10T+ inflammation economy through first-in-class, safe, upstream intervention.
Inflammation drives 75% of modern disease—yet most treatments arrive too late, too narrowly, and at too high a cost.
Sen-Jam is changing this. Our PAIR platform brings forward a simple, elegant therapeutic logic—addressing inflammation at its biological origin, with unmatched safety and scalability.
We’re redefining how medicine approaches disease prevention, longevity, and recovery—offering a new path toward preserving healthspan and transforming lives at global scale.
What We Believe
We believe unchecked inflammation is the enemy—and its first spark is our call to act.
We believe health resides upstream, not when symptoms appear.
We believe the body holds innate wisdom—and medicine should honor it.
We believe modulation is more elegant than suppression.
We believe health span is the new standard.
We don’t do sick-care. We end it.
What If We’ve Been Solving the Wrong Problem?
For decades, medicine has chased symptoms—while unchecked inflammation quietly drives disease from the inside out. Discover how one Pharmacist’s bedside insight sparked a new path forward.
A Trillion-Dollar Lever for Global Health
Sen-Jam’s PAIR-powered lead assets target four of the most devastating and costly burdens on earth—each draining trillions from lives and economies alike.
Metabolic Overload (overeating, obesity, alcohol-related stress)
$4.3 trillion—projected 3% of global GDP by 2035
The world’s most costly daily habit—reshaping metabolism, accelerating disease.
Opioid Crisis (withdrawal, dependence, tolerance)
$2.7 trillion U.S. impact in 2023 alone
A trillion-dollar hemorrhage—where safer, inflammation-driven, non-opioid solutions are urgently needed.
Respiratory Infections (COPD, URIs, COVID, RSV)
#3 global cause of death; 3.2 million COPD deaths/year
Every breath carries a toll—where unchecked inflammation turns treatable illness into tragedy.
Runaway Hospital Inflammation (Sepsis, ARDS, critical-care inflammation)
11 million deaths and $52B U.S. spend per year
In the ICU, it’s the silent driver of cost, mortality, and system strain.
PAIR turns these towering costs into opportunity—quietly, elegantly, with a safety profile we are actively proving to be a mechanism ready to reshape global health.
Next—meet the combination duo unlocking this new frontier
Two Proven Molecules, One Novel Alliance
PAIR repurposes a decades-trusted NSAID and a well-characterized mast-cell modulator, tuning their ratios so they work with—rather than against—your innate immune sentinels. By soothing mast cells while dampening COX1 and COX2 in the same breath, this dynamic duo halts the inflammatory cascade upstream, turning familiar chemistry into breakthrough, tissue-sparing relief.
When one elegant alliance can be tuned like a dial, opportunity multiplies fast. Scroll on to see how the same PAIR blueprint is already branching into eleven tailored programs—some headed for the pharmacy aisle, others for the ICU—all advancing our pipeline.
Therapeutic Pipeline
Addressing Significant Unmet Needs with a Revolutionary Combination Immuno-Inflammatory Portfolio
Prescription Strength Relief
Over the Counter Relief
Upper Respiratory Infections, including COVID
Metabolic Recovery (food and alcohol)
Opioid Use Disorder
Vaccination Side-effects
Respiratory Common Cold
Arthritis
Premature Aging